BE

Belgium

15437 clinical trials

Find Trials

Clinical Trials (15437)

Showing 20 of 15,437 trialsScroll for more
NCT07298473Not Applicable1 site

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

Recruiting
NCT03383458Phase 35 sites

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Active Not Recruiting
NCT06679140Phase 32 sites

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Recruiting
NCT03765918Phase 33 sites

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Active Not Recruiting
NCT06809322Phase 33 sites

Vorasidenib Maintenance for IDH Mutant Astrocytoma

Recruiting
NCT07071519Phase 33 sites

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

Recruiting
NCT04640623Phase 27 sites

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Active Not Recruiting
NCT07727057Not Applicable2 sites

A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatment of Ventricular Arrhythmias

Recruiting
NCT06772623Phase 14 sites

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Recruiting
NCT06007690Phase 32 sites

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Active Not Recruiting
NCT05889182Phase 37 sites

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting
NCT05876754Phase 34 sites

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

Active Not Recruiting
NCT06102590Not Applicable1 site

Oxygen Extraction-guided Transfusion

Recruiting
NCT05138133Phase 33 sites

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Active Not Recruiting
NCT07483827Phase 11 site

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

Recruiting
NCT07088926Phase 24 sites

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Recruiting
NCT06066580Phase 23 sites

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Enrolling By Invitation
NCT05352919Phase 31 site

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Enrolling By Invitation
NCT04557098Phase 22 sites

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Active Not Recruiting
NCT06667076Phase 24 sites

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting